Provided is an electric perforating device 10 including a flow passage 20 through which liquid flows, a first electrode 30A that forms a first electric field region 60A in the flow passage 20 by being supplied with a pulse voltage, a second electrode 30B that forms a second electric field region 60B on a downstream side of the first electric field region 60A, which is in the flow passage 20, in a flowing direction of the liquid, by being supplied with a pulse voltage, a cooling portion 40 that forms a cooling region 70, which cools the liquid flowing through the flow passage 20, between the first electric field region 60A and the second electric field region 60B in the flow passage 20, and a voltage output portion 50 that outputs a pulse voltage for forming the first electric field region 60A and the second electric field region 60B.

The present disclosure relates to a human cardiac tissue construct, to the method for producing thereof and its uses in disease modelling, compound screening and properties evaluation, and/or therapeutic uses in heart regeneration. It further relates to a perfusion bioreactor with electrical stimulation capabilities and its use in the production of said human cardiac tissue construct. In still a further aspect, the disclosure provides a method for the non-destructive evaluation of electrophysiological activity in a cellular construct, such as a cardiac tissue construct of the disclosure.

The presently disclosed subject matter relates generally to the delivery of electrical stimuli via cell-penetrating nanoelectrodes. Such electrical stimuli leads to differentiation of cells, including but not limited to adipose derived stem cells, to neural lineage, specifically to neural cells.

Compositions, systems, and methods for activating dendritic cells are disclosed. Also disclosed are compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase in volume of a tumor present in a body of a living subject, along with methods of treating other diseases and infections. The systems and methods involve application of an alternating electric field to dendritic cell(s) in vivo or ex vivo and/or to a subject or cancer cells isolated therefrom. The systems and methods may further include administration of activated dendritic cells to a subject. The compositions comprise populations of isolated dendritic cells activated by exposure to an alternating electric field.

A composition of matter for tissue engineering is disclosed. The composition comprises a plurality of electrospun albumin fibers, wherein an outer surface of the composition comprises a pattern of ridges or indentations, wherein the ridges or indentations are wider than the diameter of a single electrospun albumin fiber of the plurality of electrospun albumin fibers.

The present invention is based, in part, on cancer vaccine compositions or pharmaceutical compositions comprising cancer cells, monocytes, and/or osteoclasts that activate NK cells, and methods for using same to prevent and/or treat diseases such as cancer.

A method of creating a pooled platelet lysate product may include obtaining whole blood from a source; separating platelets from the whole blood using a pressurized rotating microfluidic filtration system; creating platelet rich plasma (PRP) by concentrating the platelets in plasma and removing red blood cells and white blood cells using centrifugation; centrifuging the PRP, removing the plasma, and re-suspending the PRP in the lactated ringers solution (LRS) to create concentrated PRP (C-PRP); laser activating the C-PRP to create an activated C-PRP product; freezing and thawing the activated C-PRP product at least 3 times, wherein vortexing and sonication are performed after each thaw; and reconstituting the activated C-PRP in a saline to create a platelet lysate product with a known potency.

In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.

Advanced therapy medicinal products (AMTPs) for cell therapy. In particular, a composition including stressed HT-29, HCT-116 and LoVo cells, and immunogenic stress proteins produced by these cells in response to stresses applied in vitro. The composition allows to simultaneously counteract multiple cell resistance mechanisms observed in situ in cancer cells, and is therefore suitable for vaccinating and treating cancers in human patients.

A cell activation reactor and a cell activation method are provided. The cell activation reactor includes a body, a rotating part, an upper cover, a microporous film, and multiple baffles. The body has an accommodating space, which is suitable for accommodating multiple cells and multiple magnetic beads. The rotating part is disposed in the accommodating space and includes multiple impellers. The microporous film is disposed in the accommodating space and covers multiple holes of the accommodating space. The baffles are disposed in the body. When the rotating part is driven to rotate, the interaction between the baffles and the impellers separates the cells and the magnetic beads.